These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 38429161)

  • 21. Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics.
    Jiang Y; Wu L; Zhu X; Bian H; Gao X; Xia M
    Lipids Health Dis; 2024 Apr; 23(1):95. PubMed ID: 38566209
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exploring the landscape of steatotic liver disease in the general US population.
    Ciardullo S; Carbone M; Invernizzi P; Perseghin G
    Liver Int; 2023 Nov; 43(11):2425-2433. PubMed ID: 37592856
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: A Multicenter Observational Study.
    Valenzuela-Vallejo L; Chrysafi P; Kouvari M; Guatibonza-Garcia V; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; Mingrone G; George J; Mantzoros CS
    Metabolism; 2023 Nov; 148():155694. PubMed ID: 37757973
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trends in Oxidative Balance Score and Prevalence of Metabolic Dysfunction-Associated Steatotic Liver Disease in the United States: National Health and Nutrition Examination Survey 2001 to 2018.
    Tan Z; Wu Y; Meng Y; Liu C; Deng B; Zhen J; Dong W
    Nutrients; 2023 Nov; 15(23):. PubMed ID: 38068789
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metabolic dysfunction-associated steatotic liver disease in older adults is associated with frailty and social disadvantage.
    Clayton-Chubb D; Kemp WW; Majeed A; Lubel JS; Woods RL; Tran C; Ryan J; Hodge A; Schneider HG; McNeil JJ; Roberts SK
    Liver Int; 2024 Jan; 44(1):39-51. PubMed ID: 37698034
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metabolic-Dysfunction-Associated Steatotic Liver Disease-Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments.
    Yanai H; Adachi H; Hakoshima M; Iida S; Katsuyama H
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895151
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The burden of metabolic dysfunction-associated steatotic liver disease and viral hepatitis in Saudi Arabia.
    Alqahtani SA; Abaalkhail F; Alghamdi S; Bzeizi K; Al-Hamoudi WK; Paik JM; Henry L; Al-Judaibi B; Sanai FM; Younossi ZM
    Saudi J Gastroenterol; 2024 Jun; ():. PubMed ID: 38946635
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The pathophysiology of MASLD: an immunometabolic perspective.
    Schwärzler J; Grabherr F; Grander C; Adolph TE; Tilg H
    Expert Rev Clin Immunol; 2024 Apr; 20(4):375-386. PubMed ID: 38149354
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Longitudinal Outcomes Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-analysis of 129 Studies.
    Chan KE; Ong EYH; Chung CH; Ong CEY; Koh B; Tan DJH; Lim WH; Yong JN; Xiao J; Wong ZY; Syn N; Kaewdech A; Teng M; Wang JW; Chew N; Young DY; Know A; Siddiqui MS; Huang DQ; Tamaki N; Wong VW; Mantzoros CS; Sanyal A; Noureddin M; Ng CH; Muthiah M
    Clin Gastroenterol Hepatol; 2024 Mar; 22(3):488-498.e14. PubMed ID: 37775028
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disparities in metabolic dysfunction-associated steatotic liver disease and cardiometabolic conditions in low and lower middle-income countries: a systematic analysis from the global burden of disease study 2019.
    Danpanichkul P; Suparan K; Dutta P; Kaeosri C; Sukphutanan B; Pang Y; Kulthamrongsri N; Jaisa-Aad M; Ng CH; Teng M; Nakano M; Morishita A; Alkhouri N; Yang JD; Chen VL; Kim D; Fallon MB; Diaz LA; Arab JP; Mantzoros CS; Noureddin M; Lazarus JV; Wijarnpreecha K
    Metabolism; 2024 Jun; 158():155958. PubMed ID: 38942169
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The double roles of T cell-mediated immune response in the progression of MASLD.
    Li Z; Wang S; Xu Q; Su X; Wang Y; Wang L; Zhang Y
    Biomed Pharmacother; 2024 Apr; 173():116333. PubMed ID: 38479177
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent advances in age-related metabolic dysfunction-associated steatotic liver disease.
    He QJ; Li YF; Zhao LT; Lin CT; Yu CY; Wang D
    World J Gastroenterol; 2024 Feb; 30(7):652-662. PubMed ID: 38515956
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Racial and ethnic differences and the role of unfavorable social determinants of health across steatotic liver disease subtypes in the United States.
    Ochoa-Allemant P; Marrero JA; Serper M
    Hepatol Commun; 2023 Dec; 7(12):. PubMed ID: 38051551
    [TBL] [Abstract][Full Text] [Related]  

  • 34. What Is New in Metabolic Dysfunction-Associated Steatotic Liver Disease in Lean Individuals: From Bench to Bedside.
    Danpanichkul P; Suparan K; Kim D; Wijarnpreecha K
    J Clin Med; 2024 Jan; 13(1):. PubMed ID: 38202285
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emerging therapies for MASLD and their impact on plasma lipids.
    Nguyen M; Asgharpour A; Dixon DL; Sanyal AJ; Mehta A
    Am J Prev Cardiol; 2024 Mar; 17():100638. PubMed ID: 38375066
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review.
    Chan WK; Chuah KH; Rajaram RB; Lim LL; Ratnasingam J; Vethakkan SR
    J Obes Metab Syndr; 2023 Sep; 32(3):197-213. PubMed ID: 37700494
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment Options and Continuity of Care in Metabolic-associated Fatty Liver Disease: A Multidisciplinary Approach.
    Lara-Romero C; Romero-Gómez M
    Eur Cardiol; 2024; 19():e06. PubMed ID: 38983581
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Defining an approach for therapeutic strategies in metabolic dysfunction-associated steatotic liver disease after liver transplantation.
    Siddiqui MS; Muthiah M; Satapathy SK; Patidar KR; Bhat M; Brandman D; Watt KD; Rinella M
    Hepatology; 2023 Dec; ():. PubMed ID: 38088872
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies.
    Kokkorakis M; Muzurović E; Volčanšek Š; Chakhtoura M; Hill MA; Mikhailidis DP; Mantzoros CS
    Pharmacol Rev; 2024 May; 76(3):454-499. PubMed ID: 38697855
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fatty Liver Disease: Enter the Metabolic Era.
    Wegermann K; Moylan C; Naggie S
    Curr HIV/AIDS Rep; 2023 Dec; 20(6):405-418. PubMed ID: 37882965
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.